港股異動 | 康哲藥業(0867.HK)漲11% 擬收購一家皮膚線專業公司切入醫美領域
格隆匯2月2日丨康哲藥業(0867.HK)高開高走,盤中最高見13.46港元創2018年8月份以來新高,現報12.92港元,漲幅11%,最新總市值319.22億港元。公司昨日公吿稱,擬通過全資附屬公司收購Luqa Ventures Co., Limited全部已發行股份。完成後,目標公司成為公司的全資附屬公司,其業績及資產與負債將合併入集團的賬目內。目標公司皮膚線覆蓋處方藥、醫療器械及醫學美容("醫美")護膚系列產品,與集團現有皮膚線產品產生協同效應互為助力,併為集團填補醫美護膚專業產品線,為集團介入醫美護膚領域帶來重大發展機會。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.